Which regimen has proven mortality benefit especially in African American patients with HFrEF?

Which regimen has proven mortality benefit especially in African American patients with HFrEF?

• A. Hydralazine and isosorbide dinitrate in addition to standard therapy.
• B. ACE inhibitors alone are enough.
• C. Spironolactone is the only addition recommended.
• D. Beta-blockers are contraindicated.

Answer: (A)

In HFrEF, adding a hydralazine–isosorbide dinitrate combination to standard therapy has shown a true survival benefit, especially for African American patients. Hydralazine lowers afterload by dilating arteries, while isosorbide dinitrate lowers preload by dilating veins; together they reduce the heart’s workload and improve cardiac output. This combination directly improves hemodynamics and, in turn, outcomes. The key evidence comes from the African American Heart Failure Trial, which found that adding this regimen to guideline-directed therapy reduced all-cause mortality and heart failure hospitalizations in black patients with advanced symptoms (NYHA class III–IV). Because of that demonstrated benefit, guidelines endorse using hydralazine with isosorbide dinitrate as an adjunct for African American patients who remain symptomatic despite optimal standard therapy (ACE inhibitors or ARBs, beta-blockers, diuretics, and possibly aldosterone antagonists). So, this approach is the regimen with the race-specific mortality benefit, beyond what standard therapy alone provides. It’s used in addition to standard treatments, not as a replacement, and it’s not contraindicated by the other standard heart failure therapies when monitored appropriately.

In HFrEF, adding a hydralazine–isosorbide dinitrate combination to standard therapy has shown a true survival benefit, especially for African American patients. Hydralazine lowers afterload by dilating arteries, while isosorbide dinitrate lowers preload by dilating veins; together they reduce the heart’s workload and improve cardiac output. This combination directly improves hemodynamics and, in turn, outcomes.

The key evidence comes from the African American Heart Failure Trial, which found that adding this regimen to guideline-directed therapy reduced all-cause mortality and heart failure hospitalizations in black patients with advanced symptoms (NYHA class III–IV). Because of that demonstrated benefit, guidelines endorse using hydralazine with isosorbide dinitrate as an adjunct for African American patients who remain symptomatic despite optimal standard therapy (ACE inhibitors or ARBs, beta-blockers, diuretics, and possibly aldosterone antagonists).

So, this approach is the regimen with the race-specific mortality benefit, beyond what standard therapy alone provides. It’s used in addition to standard treatments, not as a replacement, and it’s not contraindicated by the other standard heart failure therapies when monitored appropriately.